NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout

NeOnc Technologies announced Q2 2026 financial results with increased R&D spending of $2.6M (up from $0.7M YoY) to support clinical development. The company completed topline analysis of its Phase 2a NEO100 study in recurrent IDH1-mutant high-grade glioma with results to be presented August 12, 2026. NeOnc secured UAE IND approvals for both NEO100 and NEO212 programs and appointed Nasim Shomali to its Board. The company reported a net loss of $14.2M for Q2 2026 with $2.0M in cash and an undrawn $10M credit line.